Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 23.00% is 21% below its 4-year average of 29.01%, near the high end of its 4-year range (-104.96%–47.52%).
37.99% below its 12-month average of 37.09%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 47.52%.
EBITDA MARGIN
23.00%
EBITDA MARGIN AVG TTM
37.09%
EBITDA MARGIN AVG 3Y
32.23%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-37.99%
CURRENT VS 3Y AVG
-28.63%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Indivior Pharmaceuticals Inc
Market Cap
$4.48B
EBITDA Margin
23.00%
TTM Avg
37.09%
3Y Avg
32.23%
5Y Avg
N/A
Market Cap
$4.37B
EBITDA Margin
-31.52%
TTM Avg
-36.86%
3Y Avg
-49.55%
5Y Avg
-49.55%
Market Cap
$4.60B
EBITDA Margin
9.15%
TTM Avg
-7.04%
3Y Avg
-33.99%
5Y Avg
-33.99%
Market Cap
$4.64B
EBITDA Margin
7.23%
TTM Avg
7.47%
3Y Avg
7.86%
5Y Avg
7.54%
Market Cap
$4.31B
EBITDA Margin
-14.19%
TTM Avg
-47.13%
3Y Avg
-77.82%
5Y Avg
-97.39%
Market Cap
$4.70B
EBITDA Margin
5.54%
TTM Avg
4.34%
3Y Avg
-4.50%
5Y Avg
-6.75%
Market Cap
$4.78B
EBITDA Margin
-8718.32%
TTM Avg
-5172.73%
3Y Avg
-3124.55%
5Y Avg
-2649.58%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Indivior Pharmaceuticals Inc (INDV) | $4.48B | 23.00% | 37.09% | 32.23% | N/A |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.37B | -31.52% | -36.86% | -49.55% | -49.55% |
| BillionToOne, Inc. (BLLN)vs › | $4.60B | 9.15% | -7.04% | -33.99% | -33.99% |
| Option Care Health, Inc. (OPCH)vs › | $4.64B | 7.23% | 7.47% | 7.86% | 7.54% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.31B | N/A | N/A | N/A | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.31B | -14.19% | -47.13% | -77.82% | -97.39% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.70B | 5.54% | 4.34% | -4.50% | -6.75% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.73B | N/A | N/A | N/A | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.78B | -8718.32% | -5172.73% | -3124.55% | -2649.58% |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.83B | 0.40% | -9.29% | -59.36% | -227.69% |
Gross Margin
83.9%
EBITDA Margin
23.0%
Operating Margin
21.4%
Net Margin
26.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 47.52% |
| 2026-03-31 | 43.85% |
| 2025-12-31 | 35.47% |
| 2025-09-30 | 33.12% |
| 2025-06-30 | 25.50% |
| 2025-03-31 | 26.69% |
| 2024-12-31 | 33.78% |
| 2024-09-30 | 5.54% |
| 2024-06-30 | -37.46% |
| 2024-03-31 | 28.17% |
| 2023-12-31 | 23.89% |
| 2023-09-30 | -64.94% |
| 2023-06-30 | 24.28% |
| 2023-03-31 | 24.90% |
| 2022-12-31 | -104.96% |
| 2022-09-30 | 26.72% |
| 2022-06-30 | 31.22% |
| 2022-03-31 | 26.57% |
| 2021-12-31 | 21.97% |
